Sequence Variation in Mature MicroRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, a SNP in mature miR-608 and clinical outcome in CRC. Here we analysed the association between rs4919510 and benefit from peri-operative treatment in a randomised phase II trial of neoadjuvant Capecitabine and Oxaliplatin (CAPOX) followed by chemo-radiotherapy, surgery and adjuvant CAPOX ± cetuximab in high-risk locally advanced rectal cancer (LARC).A total of 155/164 (94.5%) patients were assessable. 95 (61.3%) were homozygous for CC, 55 (35.5%) heterozygous (CG) and 5 (3.2%) homozygous for GG.Median follow-up was 64.9 months. In the CAPOX arm the 5-yr progression-free survival (PFS) and overall survival (OS) rates were 54.6% and 60.7% for CC and 82.0% and 82.1% for CG/GG, respectively (HR PFS 0.13, 95% CI: 0.12-0.83, p=0.02; HR OS 0.38, 95% CI: 0.14-1.01, p=0.05). In the CAPOX-C arm PFS and OS were 73.2% and 82.2% respectively for CC carriers and 64.6% and 73.1% for CG/GG carriers (HR PFS 1.38, 95% CI: 0.61-3.13, p=0.44; HR OS 1.34, 95% CI: 0.52-3.48, p=0.55). An interaction was found between study treatment and rs4919510 genotype for both PFS (p=0.02) and OS (p=0.07).This is the first study investigating rs4919510 in LARC. The CC genotype appeared to be associated with worse prognosis compared to the CG/GG genotype in patients treated with chemotherapy and chemo-radiotherapy alone. Addition of Cetuximab to chemotherapy and chemo-radiotherapy in CC carriers appeared to improve clinical outcome.